+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05001880

Randomized Trial Comparing Chemotherapy With or Without Atezolizumab Immunotherapy and Surgery for Peritoneal Mesothelioma

Led by National Cancer Institute (NCI) · Updated on 2026-10-26

66

Participants Needed

41

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating treatments for peritoneal mesothelioma, a rare cancer affecting the lining of the abdomen. This phase II trial compares the usual combination of carboplatin, pemetrexed, and bevacizumab chemotherapy with or without the addition of atezolizumab immunotherapy. The study aims to see if adding atezolizumab improves tumor response rates and patient outcomes. Participants are randomly assigned to one of two groups. One group receives intravenous atezolizumab along with carboplatin, pemetrexed, and bevacizumab every 21 days for up to four cycles, followed by surgery and heated chemotherapy inside the abdomen HIPEC. Those unable to undergo surgery may continue maintenance treatment with atezolizumab and bevacizumab. The other group receives carboplatin, pemetrexed, and bevacizumab, also followed by surgery and HIPEC, with optional maintenance therapy at the investigators discretion. Throughout the study, patients undergo CT and PET scans and provide blood and tissue samples. Participants are closely monitored with scans and lab tests to assess tumor response, safety, and surgical outcomes. Follow-up visits occur every six months for up to three years after treatment to track progression-free and overall survival. The study also explores blood biomarkers that might predict clinical outcomes. This thorough evaluation helps researchers understand the benefits and risks of adding immunotherapy to standard chemotherapy for peritoneal mesothelioma.

CONDITIONS

Brief Title

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here